Välkommen till Cancer Collaboration Day på Medicon Village. En eftermiddag med ett fullspäckat program på temat cancer. Dagen börjar med en lunchföreläsning av Cancerkompis-ambassadören och superentreprenören Thomas EK.
Välkommen att anmäla dig via länken här: CCDay
Location: Restaurant Inspira, Medicon Village, Scheelevägen 2, Lund
Thomas Ek, Superentrepreneur and founder of OBH Nordica
Thomas will describe how he and his brother Peter managed to beat all multi international competitors when they launched a totally unknown brand, OBH Nordica. Key factors such as differentiation, speed, passion and leadership will be explained. Thomas will also talk about social responsibility and how to deal with his worst nightmare - when his brother and business partner became seriously ill in cancer. Thomas Ek is invited by Cancerkompisar.
Location: The auditorium
13.00 - 13.10 Welcome and introduction
13.10 - 14.00 Keynote session: ”Deconstructing cancer and aging in the genomic era” Carlos Lopez Otin, Professor of Biochemistry and Molecular Biology at the University of Oviedo, Spain Over recent years, the introduction of new methods for genome sequencing and analysis has allowed the molecular analysis of complex biological processes, such as cancer and aging, under a new perspective. This talk will summarize recent findings of our laboratory derived from genomic studies of patients with cancer and with premature aging syndromes.
14.00 - 14.25 Inspirational Lecture: ” Fighting skin cancer - a collaborative project” Kari Nielsen, MD, PhD, Lund Melanoma Study Group, Department of Clinical Sciences, Division of Dermatology Dr. Nielsen will focus on skin cancer research and how collaboration between disciplines and organisations is essential to achieve results.
14.25 - 14.50 Speed networking; Introduction & Coffee Why is it important to work across borders and in consortia where clinics, universities and industry collaborate in joint projects? And – how do you succeed?
14.50 - 16.00 Speed networking 16.00 - 16.20 Inspirational Lecture: ”Applicability of Immunitrack platform in identification of cancer specific neoepitope.” Stephan Thorgrimsen, CEO Immunitrack ApS Stephan will be speaking about personalized cancer vaccine where patient specific tumor mutations may represent an attractive target for immunotherapy. Here, he will address some of the current advances and challenges and importance of collaborations, and where the technology platform of Immunitrack may help making a difference.
16.20 - 16.40 Inspirational Lecture: ”A liquid biopsy for early detection of ovarian cancer” Ingrid Hedenfalk, Associate Professor, Lund University, Department of Clinical Sciences, Division of Oncology and Pathology Ovarian cancer is often called the disease that whispers due to the lack of symptoms. It is generally diagnosed in advanced stages and is therefore associated with a very poor prognosis. Early diagnosis would radically transform survival prospects. The Breast and Ovarian Cancer Genomics research group at LUCC are exploring the combined use of digital droplet PCR and deep sequencing of ovarian cancer-derived DNA in cervical smears for the development of a sensitive, non-invasive diagnostic test, a liquid biopsy. Earlier diagnosis of this lethal disease could radically transform survival prospects. Currently >70% of women diagnosed with ovarian cancer die within five years, but if the cancer is detected early, in stage I, there is a >80% chance of survival.
16.40 - 17.00 Summary/end of meeting
